View ValuationEusol BiotechLtd 将来の成長Future 基準チェック /06現在、 Eusol BiotechLtdの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長29.6%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • Mar 30New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: NT$301.4m (US$9.41m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Revenue is less than US$1m (NT$370k revenue, or US$12k). Market cap is less than US$10m (NT$301.4m market cap, or US$9.41m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).お知らせ • Mar 12Eusol Biotech Co.,Ltd., Annual General Meeting, Jun 09, 2026Eusol Biotech Co.,Ltd., Annual General Meeting, Jun 09, 2026. Location: 1 floor no,26, k`un yang st., nangang district, taipei city TaiwanNew Risk • Feb 23New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Revenue is less than US$1m (NT$370k revenue, or US$12k). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (NT$986.4m market cap, or US$31.3m).New Risk • Jan 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m (NT$370k revenue, or US$12k). Minor Risk Market cap is less than US$100m (NT$1.29b market cap, or US$41.1m).New Risk • Aug 21New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.5% average weekly change). Revenue is less than US$1m (NT$370k revenue, or US$12k). Minor Risk Market cap is less than US$100m (NT$986.4m market cap, or US$32.3m).New Risk • Apr 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.7% average weekly change). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (NT$828.9m market cap, or US$25.1m).お知らせ • Mar 13Eusol Biotech Co.,Ltd., Annual General Meeting, Jun 10, 2025Eusol Biotech Co.,Ltd., Annual General Meeting, Jun 10, 2025. Location: 1 floor no,465-1, sec.6 chung hsiao e. rd., nangang district, taipei city TaiwanNew Risk • Mar 03New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (NT$1.08b market cap, or US$32.7m).お知らせ • Mar 19Eusol Biotech Co.,Ltd., Annual General Meeting, Jun 06, 2024Eusol Biotech Co.,Ltd., Annual General Meeting, Jun 06, 2024.New Risk • Feb 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (5.7% average weekly change). Market cap is less than US$100m (NT$1.30b market cap, or US$41.2m).お知らせ • Mar 06EUSOL Biotech Co., Ltd., Annual General Meeting, May 20, 2022EUSOL Biotech Co., Ltd., Annual General Meeting, May 20, 2022.お知らせ • Mar 16EUSOL Biotech Co., Ltd., Annual General Meeting, May 31, 2021EUSOL Biotech Co., Ltd., Annual General Meeting, May 31, 2021.Is New 90 Day High Low • Mar 06New 90-day low: NT$24.45The company is down 11% from its price of NT$27.60 on 04 December 2020. The Taiwanese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period.Is New 90 Day High Low • Jan 28New 90-day low: NT$24.65The company is down 9.0% from its price of NT$27.10 on 30 October 2020. The Taiwanese market is up 23% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 15% over the same period.分析記事 • Jan 20We Think EUSOL Biotech (GTSM:6652) Can Afford To Drive Business GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, although...Is New 90 Day High Low • Jan 13New 90-day low: NT$24.85The company is down 3.0% from its price of NT$25.75 on 16 October 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 16% over the same period.Is New 90 Day High Low • Oct 12New 90-day low: NT$24.50The company is down 14% from its price of NT$28.35 on 14 July 2020. The Taiwanese market is up 4.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 16% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Eusol BiotechLtd は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TPEX:6652 - アナリストの将来予測と過去の財務データ ( )TWD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20252-40-35-33N/A9/30/20251-39-36-34N/A6/30/20250-38-36-35N/A3/31/20250-34-35-34N/A12/31/2024N/A-31-33-32N/A9/30/2024N/A-40-32-31N/A6/30/2024N/A-49-30-30N/A3/31/2024N/A-50-37-36N/A12/31/2023N/A-52-43-43N/A9/30/2023N/A-26-40-40N/A6/30/2023N/A0-37-37N/A3/31/2023N/A-9-45-45N/A12/31/2022N/A-18-53-53N/A9/30/2022N/A-61-67-66N/A6/30/2022N/A-103-80-80N/A3/31/2022N/A-113-85-84N/A12/31/2021N/A-123-90-89N/A9/30/2021N/A-117-90-89N/A6/30/2021N/A-111-91-90N/A3/31/2021N/A-113-91-90N/A12/31/2020N/A-114-92-90N/A9/30/2020N/A-115-90-86N/A6/30/2020N/A-117-88-81N/A3/31/2020N/A-112-91-82N/A12/31/2019N/A-107-94-82N/A9/30/2019N/A-123N/A-105N/A6/30/2019N/A-139N/A-128N/A3/31/2019N/A-167N/A-167N/A12/31/2018N/A-194N/A-207N/A9/30/20180-222N/A-228N/A6/30/20181-249N/A-248N/A3/31/20181-233N/A-269N/A12/31/20171-217N/A-290N/A9/30/20170-171N/A-251N/A6/30/2017N/A-125N/A-213N/A3/31/2017N/A-112N/A-149N/A12/31/2016N/A-99N/A-85N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 6652の予測収益成長が 貯蓄率 ( 1.2% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 6652の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 6652の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 6652の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 6652の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 6652の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/04/18 07:46終値2026/04/09 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Eusol Biotech Co.,Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Mar 30New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: NT$301.4m (US$9.41m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Revenue is less than US$1m (NT$370k revenue, or US$12k). Market cap is less than US$10m (NT$301.4m market cap, or US$9.41m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).
お知らせ • Mar 12Eusol Biotech Co.,Ltd., Annual General Meeting, Jun 09, 2026Eusol Biotech Co.,Ltd., Annual General Meeting, Jun 09, 2026. Location: 1 floor no,26, k`un yang st., nangang district, taipei city Taiwan
New Risk • Feb 23New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Revenue is less than US$1m (NT$370k revenue, or US$12k). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (NT$986.4m market cap, or US$31.3m).
New Risk • Jan 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m (NT$370k revenue, or US$12k). Minor Risk Market cap is less than US$100m (NT$1.29b market cap, or US$41.1m).
New Risk • Aug 21New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.5% average weekly change). Revenue is less than US$1m (NT$370k revenue, or US$12k). Minor Risk Market cap is less than US$100m (NT$986.4m market cap, or US$32.3m).
New Risk • Apr 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.7% average weekly change). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (NT$828.9m market cap, or US$25.1m).
お知らせ • Mar 13Eusol Biotech Co.,Ltd., Annual General Meeting, Jun 10, 2025Eusol Biotech Co.,Ltd., Annual General Meeting, Jun 10, 2025. Location: 1 floor no,465-1, sec.6 chung hsiao e. rd., nangang district, taipei city Taiwan
New Risk • Mar 03New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (NT$1.08b market cap, or US$32.7m).
お知らせ • Mar 19Eusol Biotech Co.,Ltd., Annual General Meeting, Jun 06, 2024Eusol Biotech Co.,Ltd., Annual General Meeting, Jun 06, 2024.
New Risk • Feb 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (5.7% average weekly change). Market cap is less than US$100m (NT$1.30b market cap, or US$41.2m).
お知らせ • Mar 06EUSOL Biotech Co., Ltd., Annual General Meeting, May 20, 2022EUSOL Biotech Co., Ltd., Annual General Meeting, May 20, 2022.
お知らせ • Mar 16EUSOL Biotech Co., Ltd., Annual General Meeting, May 31, 2021EUSOL Biotech Co., Ltd., Annual General Meeting, May 31, 2021.
Is New 90 Day High Low • Mar 06New 90-day low: NT$24.45The company is down 11% from its price of NT$27.60 on 04 December 2020. The Taiwanese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period.
Is New 90 Day High Low • Jan 28New 90-day low: NT$24.65The company is down 9.0% from its price of NT$27.10 on 30 October 2020. The Taiwanese market is up 23% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 15% over the same period.
分析記事 • Jan 20We Think EUSOL Biotech (GTSM:6652) Can Afford To Drive Business GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Is New 90 Day High Low • Jan 13New 90-day low: NT$24.85The company is down 3.0% from its price of NT$25.75 on 16 October 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 16% over the same period.
Is New 90 Day High Low • Oct 12New 90-day low: NT$24.50The company is down 14% from its price of NT$28.35 on 14 July 2020. The Taiwanese market is up 4.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 16% over the same period.